Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Polivy (polatuzumab vedotin-piiq)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer, Roche

Drug class:

Microtubule inhibitor, CD79b-targeted antibody-drug conjugate

Related drugs:

‹

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

PF-08046048 (4)

PF-08046047 (4)

belantamab mafodotin-blmf (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

›

No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1	rituximab + polatuzumab vedotin-piiq Sensitive: A1 - Approval rituximab + polatuzumab vedotin-piiq Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1	polatuzumab vedotin-piiq Sensitive: A1 - Approval polatuzumab vedotin-piiq Sensitive : A1
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials venetoclax + polatuzumab vedotin-piiq Sensitive : C3	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials venetoclax + polatuzumab vedotin-piiq Sensitive : C3